Heparin-Bridging Therapy and Risk of Bleeding After Endoscopic Submucosal Dissection for Gastric Neoplasms: a Meta-Analysis

被引：8
作者：
Jaruvongvanich V. [1 ,2 ]
Sempokuya T. [1 ]
Wijarnpreecha K. [3 ]
Ungprasert P. [4 ]
机构：
[1] Department of Internal Medicine, University of Hawaii, Honolulu, 96817, HI
[2] Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok
[3] Department of Internal Medicine, Bassett Medical Center, Cooperstown, NY
[4] Division of Clinical Epidemiology, Siriraj Medical Research Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
来源：
Journal of Gastrointestinal Cancer | 2018年 / 49卷 / 1期
关键词：
Anticoagulant; Bleeding; Endoscopic submucosal dissection; Gastric cancer; Warfarin;
D O I：
10.1007/s12029-017-0049-0
中图分类号：
学科分类号：
摘要：
Purpose: Peri-procedural heparin is recommended as bridging therapy for patients with high thromboembolic risk who need to withhold anticoagulant for endoscopic submucosal dissection (ESD) for gastric neoplasms. However, little is known about the bleeding risk from heparin-bridging therapy itself. Methods: MEDLINE and EMBASE databases were searched through August 2017 for studies that compared the risk of post-ESD bleeding in patients who received heparin-bridging therapy in lieu of anticoagulant for gastric neoplasms and those who discontinued anticoagulant without receiving heparin. Pooled risk ratio (RR) and 95% confidence interval (CI) were calculated using a random-effect model, generic inverse variance method. The between-study heterogeneity was quantified using the Q statistic and I2. Results: A total of four studies consisting of 350 patients were identified. A significantly increased risk of post-ESD bleeding among the bridged patients compared with the non-bridged patients was observed with the pooled RR of 2.99 (95% CI, 1.51 to 5.92). The statistical heterogeneity was insignificant with I2 of 0%. Conclusions: A significantly increased risk of post-ESD bleeding among patients who received heparin-bridging therapy in lieu of anticoagulant compared to patients who did not receive it was demonstrated in this study. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
页码：16 / 20
页数：4
相关论文
共 19 条
[1]  
Jemal A., Center M.M., DeSantis C., Ward E.M., Global patterns of cancer incidence and mortality rates and trends, Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 19, 8, pp. 1893-1907, (2010)
[2]  
Bhatt A., Abe S., Kumaravel A., Vargo J., Saito Y., Indications and techniques for endoscopic submucosal dissection, Am J Gastroenterol, 110, 6, pp. 784-791, (2015)
[3]  
Facciorusso A., Antonino M., Di Maso M., Muscatiello N., Endoscopic submucosal dissection vs endoscopic mucosal resection for early gastric cancer: a meta-analysis, World Journal of Gastrointestinal Endoscopy, 6, 11, pp. 555-563, (2014)
[4]  
Ajani J.A., D'Amico T.A., Almhanna K., Bentrem D.J., Chao J., Das P., Denlinger C.S., Fanta P., Farjah F., Fuchs C.S., Gerdes H., Gibson M., Glasgow R.E., Hayman J.A., Hochwald S., Hofstetter W.L., Ilson D.H., Jaroszewski D., Johung K.L., Keswani R.N., Kleinberg L.R., Korn W.M., Leong S., Linn C., Lockhart A.C., Ly Q.P., Mulcahy M.F., Orringer M.B., Perry K.A., Poultsides G.A., Scott W.J., Strong V.E., Washington M.K., Weksler B., Willett C.G., Wright C.D., Zelman D., McMillian N., Sundar H., G
[5]  
Libanio D., Costa M.N., Pimentel-Nunes P., Dinis-Ribeiro M., Risk factors for bleeding after gastric endoscopic submucosal dissection: a systematic review and meta-analysis, Gastrointest Endosc, 84, 4, pp. 572-586, (2016)
[6]  
Veitch A.M., Vanbiervliet G., Gershlick A.H., Boustiere C., Baglin T.P., Smith L.A., Radaelli F., Knight E., Gralnek I.M., Hassan C., Dumonceau J.M., Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines, Endoscopy, 48, 4, pp. 385-402, (2016)
[7]  
Acosta R.D., Abraham N.S., Chandrasekhara V., Chathadi K.V., Early D.S., Eloubeidi M.A., Evans J.A., Faulx A.L., Fisher D.A., Fonkalsrud L., Hwang J.H., Khashab M.A., Lightdale J.R., Muthusamy V.R., Pasha S.F., Saltzman J.R., Shaukat A., Shergill A.K., Wang A., Cash B.D., DeWitt J.M., The management of antithrombotic agents for patients undergoing GI endoscopy, Gastrointest Endosc, 83, 1, pp. 3-16, (2016)
[8]  
Fujimoto K., Fujishiro M., Kato M., Higuchi K., Iwakiri R., Sakamoto C., Uchiyama S., Kashiwagi A., Ogawa H., Murakami K., Mine T., Yoshino J., Kinoshita Y., Ichinose M., Matsui T., Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment, Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society, 26, 1, pp. 1-14, (2014)
[9]  
Witt D.M., Delate T., Garcia D.A., Clark N.P., Hylek E.M., Ageno W., Dentali F., Crowther M.A., Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding, Arch Intern Med, 172, 19, pp. 1484-1491, (2012)
[10]  
Broderick J.P., Bonomo J.B., Kissela B.M., Khoury J.C., Moomaw C.J., Alwell K., Woo D., Flaherty M.L., Khatri P., Adeoye O., Ferioli S., Kleindorfer D.O., Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence, Stroke, 42, 9, pp. 2509-2514, (2011)
12